Literature DB >> 30715353

Universal Influenza Virus Vaccines That Target the Conserved Hemagglutinin Stalk and Conserved Sites in the Head Domain.

Florian Krammer1, Peter Palese2,3.   

Abstract

Due to limitations of current influenza virus vaccines, new vaccines that mediate broad protection and show high efficacy against seasonal and pandemic viruses are urgently needed. The conserved stalk of the viral hemagglutinin has been identified as potential target antigen for this new generation of vaccines. A vaccination strategy based on chimeric hemagglutinin (cHA), which refocuses the immune response toward the stalk domain and the conserved neuraminidase, is currently being tested in clinical trials. Here we discuss how to improve the cHA antigens to generate vaccine candidates that both induce a broad antistalk response and target conserved immunosubdominant epitopes in the head domain of the hemagglutinin. These novel constructs, termed mosaic hemagglutinins, should provide enhanced protection and should be tested in clinical trials to assess their improved potential as universal influenza virus vaccine candidates.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  chimeric hemagglutinin; heterosubtypic immunity; influenza virus; mosaic hemagglutinin; universal influenza virus vaccines

Mesh:

Substances:

Year:  2019        PMID: 30715353      PMCID: PMC6452318          DOI: 10.1093/infdis/jiy711

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  65 in total

1.  Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly.

Authors:  J C de Jong; W E Beyer; A M Palache; G F Rimmelzwaan; A D Osterhaus
Journal:  J Med Virol       Date:  2000-05       Impact factor: 2.327

2.  Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes.

Authors:  Rong Hai; Florian Krammer; Gene S Tan; Natalie Pica; Dirk Eggink; Jad Maamary; Irina Margine; Randy A Albrecht; Peter Palese
Journal:  J Virol       Date:  2012-03-07       Impact factor: 5.103

3.  Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin.

Authors:  James R R Whittle; Ruijun Zhang; Surender Khurana; Lisa R King; Jody Manischewitz; Hana Golding; Philip R Dormitzer; Barton F Haynes; Emmanuel B Walter; M Anthony Moody; Thomas B Kepler; Hua-Xin Liao; Stephen C Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-08       Impact factor: 11.205

4.  A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin.

Authors:  Jens C Krause; Tshidi Tsibane; Terrence M Tumpey; Chelsey J Huffman; Christopher F Basler; James E Crowe
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

5.  Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies.

Authors:  Arun K Kashyap; John Steel; Ahmet F Oner; Michael A Dillon; Ryann E Swale; Katherine M Wall; Kimberly J Perry; Aleksandr Faynboym; Mahmut Ilhan; Michael Horowitz; Lawrence Horowitz; Peter Palese; Ramesh R Bhatt; Richard A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-14       Impact factor: 11.205

6.  Crystal structure of unliganded influenza B virus hemagglutinin.

Authors:  Qinghua Wang; Feng Cheng; Mingyang Lu; Xia Tian; Jianpeng Ma
Journal:  J Virol       Date:  2008-01-09       Impact factor: 5.103

7.  Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses.

Authors:  Natalie Pica; Rong Hai; Florian Krammer; Taia T Wang; Jad Maamary; Dirk Eggink; Gene S Tan; Jens C Krause; Thomas Moran; Cheryl R Stein; David Banach; Jens Wrammert; Robert B Belshe; Adolfo García-Sastre; Peter Palese
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

8.  Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection.

Authors:  Jens Wrammert; Dimitrios Koutsonanos; Gui-Mei Li; Srilatha Edupuganti; Jianhua Sui; Michael Morrissey; Megan McCausland; Ioanna Skountzou; Mady Hornig; W Ian Lipkin; Aneesh Mehta; Behzad Razavi; Carlos Del Rio; Nai-Ying Zheng; Jane-Hwei Lee; Min Huang; Zahida Ali; Kaval Kaur; Sarah Andrews; Rama Rao Amara; Youliang Wang; Suman Ranjan Das; Christopher David O'Donnell; Jon W Yewdell; Kanta Subbarao; Wayne A Marasco; Mark J Mulligan; Richard Compans; Rafi Ahmed; Patrick C Wilson
Journal:  J Exp Med       Date:  2011-01-10       Impact factor: 14.307

9.  Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses.

Authors:  Jianhua Sui; William C Hwang; Sandra Perez; Ge Wei; Daniel Aird; Li-mei Chen; Eugenio Santelli; Boguslaw Stec; Greg Cadwell; Maryam Ali; Hongquan Wan; Akikazu Murakami; Anuradha Yammanuru; Thomas Han; Nancy J Cox; Laurie A Bankston; Ruben O Donis; Robert C Liddington; Wayne A Marasco
Journal:  Nat Struct Mol Biol       Date:  2009-02-22       Impact factor: 15.369

10.  Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.

Authors:  Mark Throsby; Edward van den Brink; Mandy Jongeneelen; Leo L M Poon; Philippe Alard; Lisette Cornelissen; Arjen Bakker; Freek Cox; Els van Deventer; Yi Guan; Jindrich Cinatl; Jan ter Meulen; Ignace Lasters; Rita Carsetti; Malik Peiris; John de Kruif; Jaap Goudsmit
Journal:  PLoS One       Date:  2008-12-16       Impact factor: 3.240

View more
  30 in total

1.  Development of Influenza B Universal Vaccine Candidates Using the "Mosaic" Hemagglutinin Approach.

Authors:  Weina Sun; Ericka Kirkpatrick; Megan Ermler; Raffael Nachbagauer; Felix Broecker; Florian Krammer; Peter Palese
Journal:  J Virol       Date:  2019-05-29       Impact factor: 5.103

2.  Monoclonal Antibody Responses after Recombinant Hemagglutinin Vaccine versus Subunit Inactivated Influenza Virus Vaccine: a Comparative Study.

Authors:  Carole Henry; Anna-Karin E Palm; Henry A Utset; Min Huang; Irvin Y Ho; Nai-Ying Zheng; Theresa Fitzgerald; Karlynn E Neu; Yao-Qing Chen; Florian Krammer; John J Treanor; Andrea J Sant; David J Topham; Patrick C Wilson
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

Review 3.  Controlled Human Infection Models To Accelerate Vaccine Development.

Authors:  Robert K M Choy; A Louis Bourgeois; Christian F Ockenhouse; Richard I Walker; Rebecca L Sheets; Jorge Flores
Journal:  Clin Microbiol Rev       Date:  2022-07-06       Impact factor: 50.129

4.  Engineered Nanoparticulate Vaccines to Combat Recurring and Pandemic Influenza Threats.

Authors:  Chunhong Dong; Bao-Zhong Wang
Journal:  Adv Nanobiomed Res       Date:  2021-12-07

5.  Librator: a platform for the optimized analysis, design, and expression of mutable influenza viral antigens.

Authors:  Lei Li; Siriruk Changrob; Yanbin Fu; Olivia Stovicek; Jenna J Guthmiller; Joshua J C McGrath; Haley L Dugan; Christopher T Stamper; Nai-Ying Zheng; Min Huang; Patrick C Wilson
Journal:  Brief Bioinform       Date:  2022-03-10       Impact factor: 13.994

Review 6.  Influenza Virus and SARS-CoV-2 Vaccines.

Authors:  Adam M Sandor; Michael S Sturdivant; Jenny P Y Ting
Journal:  J Immunol       Date:  2021-05-21       Impact factor: 5.426

7.  Non-sterilizing, Infection-Permissive Vaccination With Inactivated Influenza Virus Vaccine Reshapes Subsequent Virus Infection-Induced Protective Heterosubtypic Immunity From Cellular to Humoral Cross-Reactive Immune Responses.

Authors:  Angela Choi; Lorena I Ibañez; Shirin Strohmeier; Florian Krammer; Adolfo García-Sastre; Michael Schotsaert
Journal:  Front Immunol       Date:  2020-06-09       Impact factor: 7.561

8.  A Novel Synthetic Dual Agonistic Liposomal TLR4/7 Adjuvant Promotes Broad Immune Responses in an Influenza Vaccine With Minimal Reactogenicity.

Authors:  Fumi Sato-Kaneko; Shiyin Yao; Fitzgerald S Lao; Jonathan Shpigelman; Karen Messer; Minya Pu; Nikunj M Shukla; Howard B Cottam; Michael Chan; Paul J Chu; David Burkhart; Roman Schoener; Takaji Matsutani; Dennis A Carson; Maripat Corr; Tomoko Hayashi
Journal:  Front Immunol       Date:  2020-06-19       Impact factor: 7.561

Review 9.  Targeting Antigens for Universal Influenza Vaccine Development.

Authors:  Quyen-Thi Nguyen; Young-Ki Choi
Journal:  Viruses       Date:  2021-05-24       Impact factor: 5.048

Review 10.  Selecting and Using the Appropriate Influenza Vaccine for Each Individual.

Authors:  Toshiki Sekiya; Marumi Ohno; Naoki Nomura; Chimuka Handabile; Masashi Shingai; David C Jackson; Lorena E Brown; Hiroshi Kida
Journal:  Viruses       Date:  2021-05-24       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.